Drings P, Bülzebruck H, Hruska D, Manke H G, Schuler G
Onkologie. 1986 Aug;9 Suppl 1:14-20. doi: 10.1159/000216056.
61 patients with untreated small cell lung cancer were treated with a combination of epirubicin 70 mg/m2, cyclophosphamide 1,000 mg/m2 and oncovin 2 mg every 3 weeks. The mean age of patients was 57 years. 51 patients were evaluable. 30 patients were classified to the stage limited disease, 21 patients to extensive disease. 9 complete and 23 partial remissions were achieved (remission rate 64%). The overall survival was 14 months, the mean survival of responders 16 months. 32 patients were alive at the end of the study. Performance status and extent of disease influenced significantly the result of treatment. The cytostatic activity of EPICO is comparable to three other drug combinations. The benefit of EPICO might be the lower cumulative toxicity of epirubicin and therefore enabling a longer duration of treatment.
61例未经治疗的小细胞肺癌患者接受了表柔比星70mg/m²、环磷酰胺1000mg/m²和长春新碱2mg每3周一次的联合治疗。患者的平均年龄为57岁。51例患者可评估。30例患者被归类为局限期疾病，21例患者为广泛期疾病。实现了9例完全缓解和23例部分缓解（缓解率64%）。总生存期为14个月，缓解者的平均生存期为16个月。研究结束时32例患者存活。体能状态和疾病范围显著影响治疗结果。EPICO的细胞抑制活性与其他三种药物组合相当。EPICO的优势可能在于表柔比星的累积毒性较低，因此能够延长治疗时间。
